PRMT5 AS AN ONCOGENIC TARGET: A REVIEW OF EMERGING INHIBITORS AND THEIR POTENTIAL EFFECT

Protein arginine methyl transferase 5 (PRMT5) is a type II enzyme responsible for symmetrically dimethylating arginine residues on various protein substrates, including histones and non-histone proteins. This review highlights the potential of PRMT5 inhibitors in cancer treatment, including breast cancer, lung cancer, ovarian cancer, glioblastoma, and colorectal cancer, as well as their role in drug discovery targeting PRMT5. Additionally, PRMT5 inhibitors show promise as therapeutic agents for heart disease and inflammation. PRMT5 plays a crucial regulatory role in oncogenic processes by promoting tumor proliferation, invasiveness, immune evasion, and DNA damage repair through multiple signaling pathways. This review also discusses the clinical status, current challenges, and future perspectives of PRMT5 inhibitors as therapeutic agents for cancer treatment as well as other diseases. These insights are essential for advancing the discovery of PRMT5-targeted drugs in oncology.